LumiraDx Ltd
NASDAQ:LMDX
LumiraDx Ltd
NASDAQ:LMDX
Price:
0.016 USD
Market Closed
Updated:
May 6, 2024
LumiraDx Ltd
Cash from Operating Activities
|
LumiraDx Ltd
Cash from Operating Activities Peer Comparison
Comparables:
SN
LIVN
EKF
AGL
CREO
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
LumiraDx Ltd
NASDAQ:LMDX
|
Cash from Operating Activities
-$162.1m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Smith & Nephew PLC
LSE:SN
|
Cash from Operating Activities
$608m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Cash from Operating Activities
$74.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Cash from Operating Activities
£6.3m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
12%
|
|
|
Angle PLC
LSE:AGL
|
Cash from Operating Activities
-£15m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Cash from Operating Activities
-£25.1m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is LumiraDx Ltd's Cash from Operating Activities?
Cash from Operating Activities
-162.1m
USD
-162.1m
USD
Based on the financial report for Dec 31, 2022, LumiraDx Ltd's Cash from Operating Activities amounts to -162.1m USD.
What is LumiraDx Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
-21%
-21%
Over the last year, the Cash from Operating Activities growth was -20%. The average annual Cash from Operating Activities growth rates for LumiraDx Ltd have been -21% over the past three years .
You don't have any saved screeners yet
